Weight Loss

Fat loss is the most searched and least honestly addressed topic in performance enhancement. The supplement industry has spent decades selling thermogenic formulas and appetite suppressants that produce marginal results at best. The pharmaceutical and peptide compounds that actually produce significant, sustained fat loss are in a completely different category that include different mechanisms, different outcomes, and a body of clinical evidence that supplements simply can’t match.

True North Performance carries the compounds that serious fat loss actually requires, GLP-1 receptor agonists that have redefined what pharmaceutical weight management looks like, Clenbuterol for metabolic rate and thermogenesis, and the peptide formats that make consistent dosing protocols accessible to every user. Every product independently lab tested, every manufacturer verified.

Semaglutide Canada

Semaglutide is the most talked about weight loss compound of the last decade and the clinical data justifies the attention. As the active compound in Ozempic and Wegovy, Semaglutide is a GLP-1 receptor agonist that works by mimicking a gut hormone that regulates appetite signaling and slows gastric emptying. The result is a significant and sustained reduction in hunger that produces caloric deficits most users struggle to achieve through willpower alone without the stimulant side effects, cardiovascular stress, or rebound hunger associated with traditional fat burners.

Clinical trials have documented average weight loss of 15–20% of body weight over 68 weeks in non diabetic subjects with outcomes that no supplement or traditional fat burner has come close to replicating. Semaglutide is available from True North Performance in lyophilized vial format for precise dose escalation protocols and in pre filled pen format for convenient weekly dosing.

The standard protocol starts at a low dose approximately 0.25mg weekly and escalates gradually over several weeks to the maintenance dose. Starting low and escalating slowly is the most effective approach for managing the nausea and gastrointestinal side effects that are the most common reason users discontinue GLP-1 therapy prematurely.

Tirzepatide Canada

Tirzepatide is the next generation of GLP-1 therapy, a dual GIP and GLP-1 receptor agonist that adds glucose dependent insulinotropic polypeptide (GIP) receptor activity on top of GLP-1 agonism. The addition of GIP receptor activity produces compounded appetite suppression and improved metabolic efficiency that outperforms Semaglutide in head to head clinical comparisons. Trials have documented average weight loss of 20–22% of body weight, the most significant fat loss outcomes ever recorded in a pharmaceutical trial.

For users who have plateaued on Semaglutide or who want the most potent GLP-1 option available from the start, Tirzepatide is the stronger choice. The same gradual dose escalation approach applies, starting at 2.5mg weekly and increasing based on tolerance and response.

Clenbuterol Canada

Clenbuterol is a beta-2 adrenergic agonist originally developed as a bronchodilator that has been used in performance enhancement for decades for its thermogenic and lipolytic effects. It increases metabolic rate through beta-2 receptor stimulation, raises core body temperature, and promotes fat oxidation producing measurable fat loss effects particularly when combined with a caloric deficit and cardiovascular training.

Clenbuterol works through a fundamentally different mechanism than GLP-1 peptides, it increases caloric expenditure rather than reducing caloric intake. This makes it complementary to Semaglutide and Tirzepatide in combined protocols, and a standalone option for users seeking thermogenic fat loss support without appetite based management. It is most commonly run in two week on, two week off cycles to prevent receptor downregulation, starting at 20–40mcg per day and increasing based on tolerance.

Side effects include elevated heart rate, tremors, sweating, and insomnia are dose dependent and more pronounced at higher doses. Starting conservatively and monitoring cardiovascular response is essential. Clenbuterol is not appropriate for users with pre existing cardiovascular conditions.

GLP-1 Peptides | Format Options

Semaglutide and Tirzepatide are available from True North Performance in both lyophilized vial format for users who want precise manual dose escalation through reconstitution and pre filled pen format for the most convenient weekly dosing experience. The active compound is identical in both formats. The vial format gives maximum control over dose escalation; the pen format removes all preparation steps for users who prioritize convenience and consistency.

Lab Testing in the Weight Loss Category

GLP-1 peptides require accurate concentration more than almost any compound we carry. The dose escalation protocols used for Semaglutide and Tirzepatide are calibrated around precise weekly doses, a vial that delivers 70% of stated concentration means your escalation schedule is wrong from week one, producing inadequate therapeutic effect at lower doses and potentially running too fast through the escalation at higher ones. Every weight loss compound at True North Performance is independently tested before listing because in this category, dosing accuracy is directly tied to both safety and outcome.